Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanadelumab - Takeda

Next Previous
Drug Profile

Lanadelumab - Takeda

Alternative Names: Anti-plasma kallikrein mAb; Anti-plasma kallikrein monoclonal antibody; DX-2930; Lanadelumab-flyo; OHB-401; SHP 643; TAK-743; TAKHZYRO; Takhzyro

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer Amgen; Dyax; Oak Hill Bio; Takeda; UCB
  • Class Antivirals; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III COVID 2019 infections
  • No development reported COVID-19 pneumonia; Diabetic macular oedema

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in USA (SC, Injection)
  • 24 Feb 2025 Registered for Hereditary angioedema (Prevention, In adolescents, In adults, In the elderly) in Liechtenstein, Norway, Iceland, European Union (SC)
  • 24 Feb 2025 EMA approves an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with Hereditary Angioedema

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top